All In Biotech

Drug Trial Radar · NCT07722780

Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE

Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of Premature Ejaculation

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.

Conditions

  • Premature Ejaculation

Interventions

  • VV913 2mg CapsulesDrug

    VV913 2mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

  • VV913 5mg CapsulesDrug

    VV913 5mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

  • VV913 10mg CapsulesDrug

    VV913 10mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

  • PlaceboDrug

    VV913 Placebo Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean intravaginal ejaculatory latency time (IELT) over the treatment periodTime frame: Part I: Week 4; Part II: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.